

# MANAGEMENT OF ACUTE ADRENAL INSUFFICIENCY RELATED ADVERSE EVENTS IN CHILDREN - RESULTS OF AN INTERNATIONAL SURVEY

SR Ali<sup>1,2</sup>, J Bryce<sup>2</sup>, NP Krone<sup>3</sup>, HL Claahsen-van der Grinten<sup>4</sup>, SF Ahmed<sup>1,2,5</sup>

1. Developmental Endocrinology Research Group, Royal Hospital for Children, University of Glasgow, Glasgow, UK
2. Office for Rare Conditions, University of Glasgow, Glasgow, UK
3. Department of Oncology and Metabolism, University of Sheffield, Sheffield, UK
4. Department of Paediatric Endocrinology, Amalia Childrens Hospital, Radboud University Medical Centre, Nijmegen, the Netherlands
5. Department of Medicine, Division of Endocrinology, Leiden University Medical Center, Leiden, the Netherlands

## INTRODUCTION

- Recent studies performed using I-CAH Registry data show a wide variation in the reported rate of adrenal insufficiency (AI) related adverse events (sick day episodes and adrenal crises) between centres (1)
- The definition of these events as well as their management may vary from one centre to another (2)
- A greater standardisation of the definition and management of these events would facilitate the benchmarking and comparison of care across centres

## AIM

Evaluate the level of consensus on the criteria that should be considered 'essential' for defining and managing adverse events associated with acute AI in children






## METHOD

Three groups of clinicians, encountering patients aged <18 years old, were approached to complete an online survey, these included:

- Active users of the International Congenital Adrenal Hyperplasia & International Disorders of Sex Development (I-CAH/I-DSD) Registries (n=66)
- Non-active users of I-CAH/I-DSD (n=35)
- Clinical users of the European Registries for Rare Endocrine Conditions (EuRECa) e-Reporting platform (n=10)

## RESULTS

56 (50%) respondents from I-CAH, I-DSD & EuRECa Registries (56 centres, 27 countries, 4 continents)



- Written corticosteroid management plans and one to one patient education provided by 54 (96%) & 51 (91%) clinicians, respectively
- Vomiting was the most common indication for IM hydrocortisone, reported by 34 (61%)

## CONCLUSION

Although there is considerable variation in the definition and management of AI related adverse events in children amongst specialist centres, there is also good evidence of consensus that can be used to develop standardised criteria for developing benchmarks and facilitating care improvement

## REFERENCES

1. Ali SR et al. Real-World Estimates of Adrenal Insufficiency-Related Adverse Events in Children with Congenital Adrenal Hyperplasia. J Clin Endocrinol Metab. 2021;106:e192-e203
2. Chrisp GL et al. Variations in the management of acute illness in children with congenital adrenal hyperplasia: An audit of three paediatric hospitals. Clin Endocrinol (Oxf). 2018;89:577-85.

## CONTACT INFORMATION

For further information please contact:

[Salma.Ali@glasgow.ac.uk](mailto:Salma.Ali@glasgow.ac.uk)

Visit the I-CAH Registry website:

<https://home.i-cah.org/>

